Drug for treatment of prostatitis and bph

 

(57) Abstract:

The invention relates to medicine, specifically to medicines for the treatment of prostatitis and BPH. This anti-inflammatory agent reduces the tonus of smooth muscles of the prostate, bladder neck and prostatic part of the urethra, which leads to the reduction and elimination of dysuria, nocturia, Colagiuri when prostate cancer. The invention lies in the fact that the proposed multi-component composition of essential trace elements in the composition of inorganic salts: manganese sulfate, copper sulfate, cobalt sulfate, potassium dvuhromovokislyj, sodium selenological and ammonium molybdate in the form of 2.4% introductory solution. The invention provides the improvement of ultrasonic parameters (ultrasound), reduce the frequency of nighttime urination, decrease in residual urine volume, its delay. table 4.

The invention relates to the field of medicine, specifically for the treatment of diseases of the urinary system, including those associated with inflammation of the prostate gland. This restless iron the size of a walnut, cosplays or expanding with way life even the most persistent men. Several decades ago, the prostate gland has begun to disturb the 35-40 year old men. Today, the disease affected men of all ages from teen to longevity in the world. In particular, in America prostatitis is considered an incurable disease, in Spain there is the term "Prostatic disability".

The most objective assessment of the prostate gland using ultrasound special sensor, which is inserted into the rectum and allows us to consider this gland as if in sections, without causing any injuries.

Prostatitis should be considered as a systemic disease. In most medical institutions up to the present time the most common treatment for prostate remains massage the prostate. In addition, inflammation try to make use of some drugs, hyperemia (heating gland to high temperatures) and antibiotics (in large doses).

It is known that up to 75% of the prostate gland inside formed numerous foci of purulent inflammation - closed microabcesses (the so-called ulcers). To eradicate the microflora contained in ulcers, study and pick up the antibiotics. Massage is done PEFC process, on the background of immunodeficiency. Therefore, when choosing their drug development (not antibiotics) must take it into consideration, such drugs must have an anti-inflammatory effect and to enhance the resistance of the organism, the restoration of the immunological status in General. Required course immune.

Experience shows that when cured the inflammatory process, it is virtually disappear complaints associated with adenoma of the prostate gland, which is often combined with prostatitis.

Among a considerable amount of advertising today, designed to help people suffering from these illnesses, known drugs proscar" and "optimal". This is a modern and effective tools. Doctors who have used, for example, proscar for treatment of their patients received the following results: the drug has anti-inflammatory effect and in some cases suppresses the swelling of the prostate tissue, stopping the growth of adenomas and reducing its size. Observed: a reduction in the frequency of urination, lost a sense of incomplete emptying of the bladder, there is a possibility restful sleep at night without getting up several times in the toilet. The specified medication races the treatment of prostate and BPH tools.

At the same time as the obvious drawback of this drug is extremely limited access to raw materials and, of course, the high cost. More accessible to the manufacturer (raw materials) and consumer (price) is the drug OMNIC (tamsuposin hydrochloride). Omnic is considered as similar, both in terms of their pharmacological action, the proposed tool is identical.

In particular, our proposed tool, as omnic selectively and specifically blocks the postsynaptic1A- adrenergic receptors in the smooth muscle of the prostate, at the same time decrease the symptoms of obstruction of the outflow of urine, lack of drug omnic is the complexity of chemical-technological process of obtaining the substance and its high exchange value. Our tool represents a 2.4% aqueous solution of inorganic salts: manganese sulfate; copper sulfate; cobalt sulfate; potassium Dubrovskiy; sodium acid selenological; ammonium molybdate, in the ratio(%) 86,6 : 4,35: 6,0 : 0,5 : 0,8 : 1,75 respectively.

The results of the study.

Conducted pre-complex of experimental studies on animals full of Pospolita. Taking into account the maximum available dose of the drug's components - salts of heavy metals, adopted in the world.

Based on the results of experimental data of 12 patients with a diagnosis of BPH (I-II), was chosen the most effective composition and daily intake means (shows his effectiveness with the patient, starting with a concentration of 1.7% solution) that is defined on the basis of objective and subjective data obtained from the patient, the international total score of prostate diseases, namely 8 indicators of the patient and the results of ultrasound examination authority (ultrasound). When assigning means (1,7% solution) total Bal was assessed in 12 units (table 1). The tool's efficiency is maintained until the concentration of 3.2%-aqueous solution (4 patients), which is 1.5 times less than the acceptable daily dose for the components of the solution components. In this case, the total Bal was assessed in 14 units (table 2). Optimal was 2,4% solution, as the total score (4 patients) averaged 25 units. In the summary table presents the most obvious subjective parameters marked with patients receiving different concentring, receiving means, the ultrasound showed marked reduction of adenoma of the prostate, as it reduces the swelling and residual urine volume up 32-52%.

Example 1. Patient sushchinskii C. A., 70 years. The diagnosis of adenoma of the prostate (2 tablespoons) Subjective data show:

- feeling of incomplete emptying of the bladder in more than half of the cases,

- the need to urinate less than 2 hours after the last urination (MI),

in half of the cases of MI were intermittently (twice urine produced through the catheter),

- difficulty temporary hold MI,

- feeling weak jet,

- evidence of efforts to start MI,

- frequent (up to 4 times) nightly MI, natural unsatisfactory with respect to existing urological problems and reluctance to have them until the end of life, i.e. the need to be treated.

With the consent of the patient he treated our tool with a concentration of 1.7% aqueous solution of 6 inorganic salts (see above) in the ratio 1,5 : 0,07 : 0,1 : 0,008 : 0,12 : 0,028 (g). 50 days were marked by the following effects: the absence of a clinical picture characteristic of BPH, some positive features on ultrasound (Emelichev noted the need to urinate less than 2 hours after the last MI and the same frequency MI intermittently, to start MI. At the same time preserved the frequency of night MI (up to 4 times). Index of life was estimated to be within 50%. Thus, on the background of a number of positive effects when using tools with a concentration of 1.7% of patients survived undesirable for the phenomena (swelling of the body and night MI).

Example 2. Patient Pacelt R. P., 60 years. The diagnosis of BPH (II century) Subjective data show:

- feeling of incomplete emptying of the bladder in more than half of the cases,

- the need to urinate in more than half of the cases less than 2 hours after the last urination (MI),

- difficulty temporary hold MI,

almost constantly feeling weak jet,

- evidence of efforts to MI,

- the average up 2 times a night MI, natural unsatisfactory with respect to existing adenoma with a request to specialists for deliverance from affliction.

With the consent of the patient completed the treatment our tool with a concentration of 3.2% aqueous solution of inorganic salts. 50 days were marked by the following effects: no feeling of incomplete emptying of the bladder, less than 1 time in 5 cases it was noted Patrimoine cases of low pressure urinary stream, as well as the application of a force before MI, saving the need to urinate at night up to 2 times, there was hope for the deliverance of diseases caused by BPH, noted the absence of clinical disease. Index of life was estimated to be within 50%. According to the U.S. remained a slight swelling and in some sections of the inhomogeneous structure of the body and its Central zone. Therefore, against the background of improvement of indicators of the effect of the means with a concentration of 3.2%, saved unwanted manifestations of the disease, which, however, are not leading in the development of chronic current (swelling of the body and night MI).

Example 3. Patient Kosarin N. F., 66 years. The diagnosis of BPH (II century) Before treatment were noted:

In more than half of the cases, the sensation of incomplete emptying of the bladder and the need to urinate less than 2 hours after the last urination (MI).

In more than half of the cases of MI were intermittently, and remained the difficulty of abstinence from MI.

Less than half of the cases felt a faint pressure of the urinary stream and the need for efforts to start MI.

Not less than 3 times noted nightly MI, neurolemma the Oia our tool with a concentration of 2.4% aqueous solution of inorganic salts. 50 days were marked by the following effects: less than 1 time in 5 cases there was no feeling of incomplete emptying of the bladder, disappeared the need to urinate more frequently than 2 hours; less than 1 time in 5 cases there was MI intermittently; disappeared difficulty refraining from MI; increased pressure urinary stream and there is much less effort to start MI; 3 times less frequent need to urinate at night; there is a satisfaction to the resulting effects from the funds and the index measuring the quality of life was assessed in the range of 75%. Thus, there are positive effects when using tools with a concentration of 2.4%, the patient was absent undesirable for the phenomena (swelling of the body and night MI). Data ultrasound testified reduce swelling up to 66% of the original. The clinical picture is characteristic of BPH 2 degrees, was missing.

Thus, the application of our tools with a concentration of 2.4% giving the most positive and effective results in the group of patients (4 patients) compared with the use of tools with a concentration of 1.7% and 3.2%.

Sources of information

1. The drug proscar" // drugs in Russia. References: is rst. 7 edition. 2000, S. 1519, 680.

Drug for treatment of prostatitis and BPH, reduces the tonus of smooth muscles of the prostate gland, reduction and elimination of dysuria, nocturia, policiuri when adenome prostate gland, characterized in that it is a 1,7 - 3,2%, preferably 2,4% aqueous solution of inorganic salts, including manganese sulfate, copper sulfate, cobalt sulfate, potassium dvuhromovokislyj, sodium acid selenological, ammonium molybdate in the ratio, %: (1,5 - 2,8) : (0,07 - 0,1) : (0,1 - 0,18) : (0,008 - 0,015) : (0,012 - 0,039) : (0,028 - 0,06), preferably 1,7 : 0,087 : 0,12 : 0,01 : 0,016 : 0,035% respectively.

 

Same patents:
The invention relates to medicine, in particular to urology, and can be used for the treatment of benign prostatic hyperplasia

Rectal tool // 2152204
The invention relates to medicine and pharmaceutical industry and for the creation of new drugs used for the treatment of acute and chronic prostatitis

The invention relates to medicine, more specifically to dermatology, and can be used for the treatment of benign tumors (adenoma, fibroma), including viral etiology (all forms of warts, molluscum contagiosum), and precancerous diseases of the skin (keratosis, keratoacanthoma, cylindroma etc)
The invention relates to medicine, dermatology
The invention relates to medicine, namely to surgery, and is intended for the treatment of nonhealing wounds and trophic ulcers

The invention relates to the field of veterinary medicine, relates to a method of increasing the viability of young cattle and can be used for the prevention of non-communicable diseases and increase the integrity of the calves in the postnatal period

The invention relates to the development of burns and wound healing medicines and can be used in medical practice to disinfect and speed the healing of skin after thermal, chemical and radiation burns, and also for the treatment of wounds, cuts, frostbite and other skin lesions with concurrent analgesic effect
The invention relates to ophthalmology

The invention relates to effervescent tablets or granules containing the frame material, the main component of sipacate, the acid component of sipacate, sweetener, as well as macro - and micronutrients and possibly vitamins as active substances

The invention relates to the field of medicine and relates to wound healing, anti-inflammatory and antiseptic funds

The invention relates to ophthalmology and is designed to repair damaged corneal endothelium

The invention relates to medicine, in particular to a gastroenterologist, and can be used for the integrated treatment of opisthorchiasis

The invention relates to effervescent tablets or granules containing the frame material, the main component of sipacate, the acid component of sipacate, sweetener, as well as macro - and micronutrients and possibly vitamins as active substances

The invention relates to animal breeding and fur farming and can be used for the prevention and treatment of iron deficiency anemia and enhance the growth of fur-bearing animals, farm and domestic animals, as well as to maintain the microelemental composition of the feed

The invention relates to the field of radiomedicine and may find application in the treatment of radioactive lesions in humans
Up!